Ruchi Garg, MD

home / authors / ruchi-garg-md

Articles

Molecular Subtyping Leads to New Targeted Trials in Endometrial Cancer

Molecular Subtyping Leads to New Targeted Trials in Endometrial Cancer

Ruchi Garg, MD
September 11th 2023

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

Ongoing Trials to Watch in Recurrent Endometrial Cancer

Ongoing Trials to Watch in Recurrent Endometrial Cancer

Ruchi Garg, MD
August 17th 2023

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

Evolving Role of Immunotherapy in Endometrial Cancer

Evolving Role of Immunotherapy in Endometrial Cancer

Ruchi Garg, MD
July 6th 2023

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer

Pushing Forward With Molecularly-Driven Precision Medicine in Endometrial Cancer

Nichole Tucker;Ruchi Garg, MD
June 23rd 2023

In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.

Garg on Treatment Paradigms for Patients With Endometrial Cancer

Garg on Treatment Paradigms for Patients With Endometrial Cancer

Ruchi Garg, MD
June 21st 2023

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
FDA Grants Fast Track Designation to Lasofoxifene for ER+, ESR1-Mutant Metastatic Breast Cancer
Published: May 29th 2019 | Updated: October 23rd 2024
FDA Grants Fast Track Designation to Lasofoxifene for ER+, ESR1-Mutant Metastatic Breast Cancer
Part 2: Factors for Selecting a Novel Hormonal Therapy for nmCRPC
Published: March 4th 2022 | Updated: October 23rd 2024
Part 2: Factors for Selecting a Novel Hormonal Therapy for nmCRPC
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: October 23rd 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Revolutionizing CLL Care With Targeted and Cellular Therapies
Published: October 19th 2024 | Updated: October 23rd 2024
Revolutionizing CLL Care With Targeted and Cellular Therapies
Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC
Published: October 19th 2024 | Updated: October 23rd 2024
Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC